Please login to the form below

Not currently logged in
Email:
Password:

Drug prices

This page shows the latest Drug prices news and features for those working in and with pharma, biotech and healthcare.

NHS England sees off AbbVie's Hep C legal challenge

NHS England sees off AbbVie's Hep C legal challenge

The court victory - and NHS England's reaction to it - reflect its growing confidence in its use of tough negotiations and procurement to drive down drug prices and strike access deals ... This is said to involve cutting prices for a course of treatment

Latest news

  • Drug pricing is pharma’s top concern in 2019 Drug pricing is pharma’s top concern in 2019

    Unphased by the data, Trump told a cabinet meeting this week that “you’re going to see a tremendous reduction in drug prices” this year, adding that the Department of Health ... That is borne out by another poll by Politico/Harvard poll which finds

  • Brexit contributes to surge in generic drug prices Brexit contributes to surge in generic drug prices

    Others drugs seeing prices rises in 2018 include Allopurinol, Bicalutamide, Latanoprost, and more recently, Naproxen. ... using its new data gathering powers to identify stock levels and manufacturer selling out prices to determine concessionary prices.".

  • FDA takes aim at pharma’s biosimilar-delaying tactics FDA takes aim at pharma’s biosimilar-delaying tactics

    He said there have been cases of biologic drug producers using these systems as an excuse not to supply biosimilar developers with the reference samples needed to carry out the necessary ... And we’ll be taking additional actions. We’re actively

  • Reference price bill tabled in US House and Senate Reference price bill tabled in US House and Senate

    making it less likely that President Trump’s plans to restrict drug prices would make it onto the legislature. ... Khanna. “This bill will bring down drug prices by taking on monopolies and boosting prescription drug competition.”.

  • Healthcare sector bullish despite political uncertainty Healthcare sector bullish despite political uncertainty

    transition. Across the Atlantic the big topic has been drug pricing, but despite the rhetoric coming out of the White House, most of the those polled (92%) do not think there ... Drug prices are expected to keep rising, but at a muted pace,” says the

More from news
Approximately 10 fully matching, plus 154 partially matching documents found.

Latest Intelligence

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    Discontinuation of modulation, although existing modulated prices can remain. Price increases will continue to need approval from DHSC, with a new provision for price increase approvals if there is evidence that ... I do not believe the government wants

  • Comment: the new UK pricing deal – welcome news, but lessons to be learned Comment: the new UK pricing deal – welcome news, but lessons to be learned

    There is no conceivable scenario in which any government would accept the political risk of reducing the threshold: every patient denied access to a drug as a result would be a ... I do not believe the Government wants to be trapped in a situation where

  • Deal Watch October 2018

    US drug prices. In other news from the US, there are now expectations of a legislative stalemate following the mid‐term elections in early November. ... It is worth remembering that there are still a few areas where both political parties are prepared

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Trump had tweeted days before that Pfizer “should be ashamed that they have raised drug prices for no reason”, claiming they were “taking advantage of the poor and others unable to ... The Trump administration has also just floated the idea of

  • The NHS and ABPI at 70: inching closer to the triple win The NHS and ABPI at 70: inching closer to the triple win

    Quizzed about disagreements. over drug prices, Stevens played down the suggestion of an adversarial approach. ... While the drug is an undoubted breakthrough in the disease, NHS England says the company needs to lower its prices before it can allow

More from intelligence
Approximately 2 fully matching, plus 22 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    Part 1: Segmentation and comparator choice - lessons for cancer drug market access in Germany. ... How to prepare. Germany is one of the largest pharmaceutical markets in Europe and drug prices there are used as reference prices in other markets.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics